Board of Directors
Ed Addison
Chairman and CEO of Cloud Pharmaceuticals
Mr. Addison is CEO of Cloud Pharmaceuticals. With a background in biomedical engineering and business, Addison is an established serial entrepreneur in both information technology and the life sciences. He is also a director for Quantum Cures Foundation. Addison's recent career focus has been on life sciences ventures that have a significant IT underpinning. Prior to Cloud Pharmaceuticals, he was CTO at Inclinix in Wilmington, NC, advisor to BioFortis and BioSequent, and CEO of several IT ventures.
Rob Armstrong, PhD
Former VP Discovery Chemistry and Research Technologies for Lilly
Rob Armstrong is the Chief Executive Officer, board member, and co-founder of Boston Pharmaceuticals. With over twenty years of experience working in research and development in the biopharmaceutical industry, Dr. Armstrong has been involved in the discovery and clinical development of programs across multiple disease areas. Dr. Armstrong created and led the small molecule R&D organization at Amgen in Thousand Oaks, CA. He subsequently co-led research at Lilly as Vice President of Global Medicinal Chemistry, was head of the translational medicine group Chorus, and was Vice President of Global External R&D. He served on the finance and scientific advisory boards of Lilly BioVentures. Prior to working in industry, Dr. Armstrong was a tenured Professor of Chemistry and Biochemistry at the University of California at Los Angeles. He received his BS in chemistry at UCSD, his Ph.D. in chemistry at CSU, and was an NIH postdoctoral fellow at Harvard. He is an advisor to Gelesis and serves on the board of directors of early stage biotechnology companies Curza Therapeutics, Cloud Pharmaceuticals, Entrega Bio, and Artax Biopharma.
Michael Brennan, MD-PhD
Founder and Former CEO of Gene Logic
Dr. Brennan is the founder, president, and former CEO of Gene Logic (NASDAQ: GLGC). His experience as successful entrepreneur for a biotech company that uses information as a key part of its business model translates especially well to Cloud Pharmaceuticals. During Dr. Brennan’s time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. Dr. Brennan was previously a general partner at Oxford Bioscience Partners. He also served as vice president, business development for Boehringer Mannheim Therapeutics.
Shahar Keinan, PhD
CSO of Cloud Pharmaceuticals
Dr. Keinan has extensive experience in the field of computational and theoretical chemistry. She has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors.
Lawrence Husick
CIO of Cloud Pharmaceuticals
Mr. Husick has twenty-seven years of experience as a chemist, technology consultant, computer system designer, software author, and company founder, as well as twenty-four years of experience as an intellectual property lawyer. This diverse background gives him a unique perspective on the issues of management and innovation.
Michael Sikora
COO of Holland and Knight, LLP
Mr. Sikora is a CPA and business executive. He is currently the COO for the law firm Finnegan, Henderson, Farrabow, Garett & Dunner. He offers Cloud Pharmaceuticals strategic and tactical advice on a broad range of issues including merger/acquisition evaluation, due diligence and integration, and operational and financial matters.
Chairman and CEO of Cloud Pharmaceuticals
Mr. Addison is CEO of Cloud Pharmaceuticals. With a background in biomedical engineering and business, Addison is an established serial entrepreneur in both information technology and the life sciences. He is also a director for Quantum Cures Foundation. Addison's recent career focus has been on life sciences ventures that have a significant IT underpinning. Prior to Cloud Pharmaceuticals, he was CTO at Inclinix in Wilmington, NC, advisor to BioFortis and BioSequent, and CEO of several IT ventures.
Rob Armstrong, PhD
Former VP Discovery Chemistry and Research Technologies for Lilly
Rob Armstrong is the Chief Executive Officer, board member, and co-founder of Boston Pharmaceuticals. With over twenty years of experience working in research and development in the biopharmaceutical industry, Dr. Armstrong has been involved in the discovery and clinical development of programs across multiple disease areas. Dr. Armstrong created and led the small molecule R&D organization at Amgen in Thousand Oaks, CA. He subsequently co-led research at Lilly as Vice President of Global Medicinal Chemistry, was head of the translational medicine group Chorus, and was Vice President of Global External R&D. He served on the finance and scientific advisory boards of Lilly BioVentures. Prior to working in industry, Dr. Armstrong was a tenured Professor of Chemistry and Biochemistry at the University of California at Los Angeles. He received his BS in chemistry at UCSD, his Ph.D. in chemistry at CSU, and was an NIH postdoctoral fellow at Harvard. He is an advisor to Gelesis and serves on the board of directors of early stage biotechnology companies Curza Therapeutics, Cloud Pharmaceuticals, Entrega Bio, and Artax Biopharma.
Michael Brennan, MD-PhD
Founder and Former CEO of Gene Logic
Dr. Brennan is the founder, president, and former CEO of Gene Logic (NASDAQ: GLGC). His experience as successful entrepreneur for a biotech company that uses information as a key part of its business model translates especially well to Cloud Pharmaceuticals. During Dr. Brennan’s time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. Dr. Brennan was previously a general partner at Oxford Bioscience Partners. He also served as vice president, business development for Boehringer Mannheim Therapeutics.
Shahar Keinan, PhD
CSO of Cloud Pharmaceuticals
Dr. Keinan has extensive experience in the field of computational and theoretical chemistry. She has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors.
Lawrence Husick
CIO of Cloud Pharmaceuticals
Mr. Husick has twenty-seven years of experience as a chemist, technology consultant, computer system designer, software author, and company founder, as well as twenty-four years of experience as an intellectual property lawyer. This diverse background gives him a unique perspective on the issues of management and innovation.
Michael Sikora
COO of Holland and Knight, LLP
Mr. Sikora is a CPA and business executive. He is currently the COO for the law firm Finnegan, Henderson, Farrabow, Garett & Dunner. He offers Cloud Pharmaceuticals strategic and tactical advice on a broad range of issues including merger/acquisition evaluation, due diligence and integration, and operational and financial matters.
